Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Sinovac Biotech Ltd. SVA
$6.47
На 18:04, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
642436735.00000000
-
week52high
6.47
-
week52low
6.47
-
Revenue
1492761000
-
P/E TTM
5967
-
Beta
0.00000000
-
EPS
0.97100000
-
Last Dividend
0.00000000
-
Next Earnings Date
30 янв 2023 г. в 21:00
Описание компании
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
Рекомендации
аналитиков
Рекомендации аналитиков
Grading company | New grade | Previous grade | Recommendation date |
---|---|---|---|
Morgan Stanley | Overweight | 20 мар 2014 г. | |
Aegis Capital | Buy | Buy | 13 ноя 2013 г. |
Aegis Capital | Buy | Hold | 15 авг 2013 г. |
Morgan Stanley | Equal-Weight | Underperform | 15 мая 2013 г. |
Aegis Capital | Hold | Hold | 14 мар 2013 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
---|---|---|---|---|
IFG INVESTMENTS SERVICES INC | D | 0 | 6027870 | 04 ноя 2003 г. |
BOWERING TERRY G | D | 0 | 6544830 | 24 сент 2003 г. |
IFG INVESTMENTS SERVICES INC | D | 0 | 6027870 | 24 сент 2003 г. |
Новостная лента
Sinovac's COVID-19 Vaccine With Pfizer Booster Less Effective Against Omicron: Reuters
Benzinga
03 янв 2022 г. в 07:23
China-based Sinovac Biotech Ltd's (NASDAQ: SVA) two-dose COVID-19 vaccine followed by a booster Pfizer Inc (NYSE: PFE) -BioNTech SE (NASDAQ: BNTX) shot showed a lower immune response against the Omicron variant compared with other strains, according to a study. The study was conducted by researchers from Yale University, the Dominican Republic's Ministry of Health, and other institutions.